TVM CAPITAL
TVM CAPITAL is a Pre-seed, Seed, Series A, Series B and Series C+ fund in the US, Europe, Middle East, North Africa and Southeast Asia investing in AI, Healthcare, oncology, immunology, diabetes, cns-neurodegeneration, pain, cardiovascular-diseases, rare-diseases, diagnostics, medical-devices and pharmaceuticals.
- Stages
- Pre-seed, Seed, Series A, Series B, Series C+
- Sectors
- AI, Healthcare, oncology, immunology, diabetes, cns-neurodegeneration, pain, cardiovascular-diseases, rare-diseases, diagnostics, medical-devices, pharmaceuticals
- Invests in
- US-wide, Europe, Middle East, North Africa, Southeast Asia
- Actively investing
- Yes
- Founded
- 1984
- Assets under management
- $900M
- Website
- tvm-capital.com
Check size not disclosed
Thesis
TVM Capital Life Science, established in 1984, focuses exclusively on the life sciences sector since 2012. The firm employs a dual-pronged investment strategy: financing innovative early-stage therapeutics through a single-asset company approach, leveraging its strategic partnership with Eli Lilly and Company, and investing in differentiated commercial-stage medical technologies, diagnostics, digital health products, and late-stage therapeutics. TVM Capital Healthcare focuses on healthcare and life sciences companies across emerging markets, including the Middle East, North Africa, and Southeast Asia. TVM Capital Healthcare seeks to address unmet healthcare needs in its target markets and provide access to affordable, innovative, quality healthcare services and products. TVM Capital Life Science manages approximately $900 million in assets under management (AUM).
Common questions
Does TVM CAPITAL invest at the Pre-seed stage?
Yes. TVM CAPITAL lists Pre-seed, Seed, Series A, Series B and Series C+ among the stages it invests in.
Where does TVM CAPITAL invest?
TVM CAPITAL invests in the US, Europe, Middle East, North Africa and Southeast Asia.